152 353

Cited 5 times in

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author한소정-
dc.date.accessioned2020-09-29T04:51:13Z-
dc.date.available2020-09-29T04:51:13Z-
dc.date.issued2020-07-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179518-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular*-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms*-
dc.subject.MESHNivolumab-
dc.subject.MESHPhenylurea Compounds-
dc.subject.MESHPyridines-
dc.subject.MESHSorafenib-
dc.titleOptimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSojung Han-
dc.contributor.googleauthorDo Young Kim-
dc.identifier.doi10.3350/cmh.2020.0096-
dc.contributor.localIdA00385-
dc.contributor.localIdA05438-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid32646205-
dc.subject.keywordCarcinoma, Hepatocellular-
dc.subject.keywordSorafenib-
dc.subject.keywordProtein kinase inhibitors-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor한소정-
dc.citation.volume26-
dc.citation.number3-
dc.citation.startPage305-
dc.citation.endPage308-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.26(3) : 305-308, 2020-07-
dc.identifier.rimsid67170-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.